Abstract Library

#4306 EVENET: Randomised phase II trial of everolimus 5mg vs. 10mg daily in patients with neuroendocrine tumours

Introduction: Everolimus 10mg PO daily is approved for patients (pts) with advanced G1/G2 neuroendocrine tumours (NET) but is associated with significant toxicity, including 20% of serious infections in real-world pts. In phase I trials, 5mg/day was sufficient to inhibit the mTOR pathway. Retrospective data suggest that 5mg/day is similarly effective to 10mg/day but less toxic.

Conference:

Presenting Author:

Authors: Riechelmann R, Campos A, Durant L, Bulzico D,

Keywords: everolimus, neuroendocrine tumour, dose optimisation, toxicity,

#3357 Sars-Cov-2 pandemic and PRRT: The experience of European Institute of Oncology (IEO), Milano, Italy

Introduction: The importance of timely assistance in oncological patients is undeniable; however it is well known that these patients could have important clinical problems if they were infected by COVID-19, with an increased risk of severe illness and mortality. A recent multicenter Italian study reported a delay both in the beginning of PRRT for new patients and in those ones who had already started the treatment, as a direct consequence of COVID-19.

Conference:

Presenting Author: Grana C

Authors: Grana C, Fazio N, Spada F, Rocca P, Laffi A,

Keywords: PRRT, GEP-NET, COVID-19,

#3247 The impact of COVID-19 pandemic on oncological care in neuroendocrine patients - A single-institution experience

Introduction: Since the first cases during the month of December 2019, coronavirus disease (COVID-19) evolved into a worldwide emergency. At the Humanitas Cancer Center, we have been operating at the epicenter of the European outbreak since the end of February, when the first Italian case was registered. Our government imposed a general lockdown from March to June in order to limit the spread of the infection across the population.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Smiroldo V

Authors: Smiroldo V, Zerbi A, Lavezzi E, Nappo G, Capretti G,

Keywords: covid-19, neuroendocrine tumor, telemedicine,

#3038 Managing Neuroendocrine Neoplasms (NEN) in Association with HIV Infection: A Single Institution Experience

Introduction: There is a paucity of knowledge regarding NEN and HIV infection in the literature.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Hayes A, Smith K, Liu M, Jenkinson S, Grossman A,

Keywords: Neuroendocrine, Carcinoid, Merkel cell carcinoma, Human immunodeficiency virus, HIV, Prognosis,

#2203 A Case of Rectal Abscess Emerged Immediately after Starting Chemotherapy with Everolimus and Required Surgical Drainage

Introduction: Everolimus is widely used for unresectable panNET. For its efficacy as an immunosuppressant, infectious adverse events are well-known.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Nakano K, Masui T, Yogo A, Uchida Y, Sato A,

Keywords: everolimus, infection, abscess, rectal abscess, surgery, drainage,